CTOs on the Move

Pharvaris

www.pharvaris.com

 
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.pharvaris.com
  • 1 Cranberry Hill Suite 300
    Lexington, MA USA 02421
  • Phone: 212.845.4262

Executives

Name Title Contact Details
Stefan Abele
 Chief Technical Operations Officer Profile

Similar Companies

Regulatory Applications and Strategy Consulting

Regulatory Applications and Strategy Consulting is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VistaGen

VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen`s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, tasteless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen`s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. With an experienced leadership team, VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression.

Roche

Roche is a multinational healthcare company that creates innovative medicines and diagnostic tests to prevent, diagnose, and treat diseases. The company is committed to improving lives and making a sustainable contribution to society.

Mission Pharmacal

Mission Pharmacal is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Kyowa Kirin

Kyowa Kirin Co., Ltd.